meta
|
evidence
COVID-19
Living systematic review and meta-analysis
IFN beta-1a
All
potential COVID-19 treatments
adjuvant therapies
anticoagulant
anticoagulant, curative dose
anticoagulant, pre-admission
anticoagulant, prophylactic dose
anticoagulation, intermediate prophylactic dose
Bivalirudin
enoxaparin
heparin at therapeutic dose
P2Y12 inhibitors
rivaroxaban
sulodexide
face mask
febuxostat
hydrogen-oxygen nebulizer
hyperbaric oxygen
nintedanib
paracetamol
pulmonary rehabilitation
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab
otilimab
clarithromycine
colchicine
Colchicine plus rosuvastatin
mepolizumab
naproxen, ibuprofen
non-steroidal anti-inflammatory drugs
Celecoxib
Ibuprofen
Indomethacin
selinexor
sodium aescinate
stem cells
tradipitant
vilobelimab (IFX-1)
Apilimod
corticosteroids
ciclesonide
dexamethasone
Dexamethasone 12mg
dexamethasone 6mg
Hydrocortisone
low-dose corticosteroids
methylprednisolone
Immunostimulants drugs
anti-PD-1 antibody
CD24Fc
convalescent plasma treatment
Deferred Convalescent plasma
Early convalescent plasma.
immunoglobulin therapy
inactivated mycobacterium vaccine
interferon
IFN beta-1a
high-dose IFN beta-1a
IFN beta-1b
IFN gamma
inhaled interferon
IFN alpha
pegylated interferon-α2b
recombinant super-compound interferon rSIFN-co
SNG001 inhaled interferon beta
interferon / TFF2
peginterferon
PNB001
Interleukin-2
levamisole
neutralizing antibody
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)
bamlanivimab monotherapy
bamlanivimab/etesevimab
Bebtelovimab (LY-CoV1404)
bevacizumab
cilgavimab and tixagevimab (Evusheld)
equine polyclonal antibodies INM005
regdanvimab (Regkirona- CT-P59-Celltrion)
sotrovimab (Xevudy; VIR-7831)
XAV-19
rhG-CSF
Immunosuppressants drugs
adalimumab
anakinra
anti-interleukin-6
clazakizumab
Levilimab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
canakinumab
complement inhibitors
conestat alfa
ravulizumab
CRAC-channel inhibitors (auxora)
eculizumab
emapalumab
fostamatinib
itolizumab
ixekizumab
jakotinib
janus kinase (JAK) inhibitor
baricitinib
baricitinib plus remdesivir
ruxolitinib
TD-0903
TD-0903 10mg
TD-0903 1mg
TD-0903 3mg
tofacitinib
lenzilumab
pamrevlumab
tacrolimus
tetrandrine
thalidomide
inhaled corticosteroids
budesonide
Kinase inhibitors
acalabrutinib
imatinib
leflunomide
meplazumab
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
statins
Atorvastatin
thymosin
antiandrogenic
5-alpha-reductase inhibitors
dutasteride
progesterone
proxalutamide
antiviral and associated therapy
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
bromhexine
carrimycin
chloroquine and derivatives
chloroquine
hydroxychloroquine
zinc plus hydroxychloroquine
danoprevir / ritonavir
darunavir cobicistat
darunavir/cobicistat plus chloroquine
doxycycline
Emtricitabine/tenofovir plus colchicine plus rosuvastatin
favipiravir
favipiravir plus interferon
fluvoxamine
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine
Interferon plus lopinavir/ritonavir
ivermectin
ivermectin plus doxycycline
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
Lopinavir/ritonavir plus hydroxychloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
molnupiravir
niclosamide
nirmatrelvir / ritonavir (Paxlovid)
nitazoxanide
opaganib
oseltamivir
oseltamivir plus chloroquin
remdesivir
ribavirin
ritonavir
sofosbuvir
sofosbuvir and daclatasvir
sofosbuvir and ledipasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
tranilast
triazavirin
umifenovir (arbidol)
zinc
control
placebo
prone positioning
standard of care
miscellaneous
acetylcysteine
alpha lipoic acid
anti-CK2
Aspirin
aviptadil
calcium channel blocker
camostat mesilate
Cannabidiol
continuous positive airway pressure (CPAP)
cytokine adsorption
diammonium glycyrrhizinate
dipyridamol
dornase alfa
expectorants and mucolytics
kinin-kallikrein inhibitors
melatonin
mouthrise and gargling agents
mouthrinses
N-Acetylcysteine
nasal spray
nasal spray containing Iota-Carrageenan
natural killer (NK) cells
nicotin
nigella sativa oil
nitric oxide (gas Inhalation or releasing solution)
omega-3 Polyunsaturated Fatty Acids
ozonated autohemotherapy
plasma exchange
povidone-iodine
previfenon (EGCG)
prostacyclin
PUL-042 inhalation solution
pyridostigmine
radiotherapy
sabizabulin
sildenafil
triiodothyronine (T3)
Oral antidiabetic drugs
dapagliflozin
DPP-4 inhibitor
metformin
Renin-angiotensin-system-acting agents
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
losartan
angiotensin-(1-7)
continuation of ACEI/ARB
discontinuation of ACEI/ARB
RAS blocker withdrawal
rhACE2
vaccines
BCG vaccination
CoVLP (MT-2766, Medicago)
DNA vaccine
Zy-Cov-D (Zydus Cadila)
ebola vaccine
first booster dose
heterologous prime-boost
Inactivated virus vaccine
CoronaVac (SinoVac)
Covaxin, Bharat Biotech (BBV152)
Shifa-Pharmed inactivated vaccine
Sinopharm Beijing (BBIBP-CorV)
Sinopharm Wuhan
mRNA vaccine
Comirnaty (tozinameran - Pfizer/BIONTECH)
CureVac
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)
Non replicating viral vector
Ad26.RSV.preF (respiratory syncytial virus)
Ad26.ZEBOV ()
Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine)
CanSino (Convidecia)
Covishield (Oxford/AZ formulation)
Janssen AD26 vaccine (JNJ-78436735)
Sputnik V (Gam-COVID-Vac)
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
protein subunit vaccine
Anhui Zhifei Longcom
CoVax-19 SpikoGen
Nuvaxovid (NVX-CoV2373) Novavax
Sanofi/GSK recombinant protein vaccine
SCB-2019
Replicating Viral Vector
seasonal influenza vaccines
virus-like particles vaccine
Medicago
Vitamins
vitamin C
zinc plus vitamin c
Vitamin D
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention
vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. Immunostimulants drugs
vs. interferon
vs. IFN beta-1a
vs. control
vs. placebo
vs. standard of care
patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Studies
Mapping
Meta-analysis
Excluded
0
table
network
network 2
select an endpoint to display result....
display studies
----
color = results
color = ROB
demonstrated
suggested
inconclusive
safety concern
ongoing study
not assessable
low
moderate
serious
ongoing study
display ongoing
demontrated benefit only
Nothing for this selection!